Biosimilars

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

DDW Highlights: 24 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers found an unexpected drug could help treat depression. Elsewhere, a new company is… Read More

#Podcasts

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

This week in Drug Discovery (16 – 20 February) 

News round-up for 16 – 20 February by Bruno Quinney, Content Team at DDW.  This week in DDW, an unexpected drug could help treat depression. Elsewhere, a new company is set to advance a cerebral palsy therapy.  The top stories:    Psychedelic drug could help treat depression … Read More

#News

Doctor points at child's brain scan
#Biosimilars #Cerebral Palsy #Thermo Fisher Scientific #Treehill Partners

New company to advance cerebral palsy therapy 

A new regenerative medicine company is set to develop a novel cell and gene therapy targeting paediatric cerebral palsy (CP).  Kidswell USA has been formed by a partnership between biosimilars and cell therapies company Kidswell Bio Corporation and corporate development advisor Treehill Partners.  In the new company, Kidswell and Treehill aim to advance their… Read More

#News

Europe
#Arthritis #Biosimilars #Europe #NHS #Ulcerative colitis (UC)

Alvotech launches Simponi biosimilar in Europe 

Biotechnology company Alvotech has announced the European launch of its first-in-market biosimilar to Simponi (golimumab).  AVT05, known as Gobivaz, is a prefilled syringe and autoinjector used for the treatment of adults with rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, as well as in children with ulcerative colitis. Gobivaz becomes the first marketed biosimilar to… Read More

#News

Medical researcher
#Antibodies #App note #Biosimilars #Kinetics #Screening

App Note: Kinetic screening for rapid biosimilar testing

A new App Note is now available for download entitled ‘Fcγ Receptor and Antigen Kinetic Screening for Rapid Biosimilar Downstream Processing Assessment’. Demonstrating similarity of biomolecules such as antibodies throughout upstream and downstream production processes is crucial. A rapid testing method is demonstrated using a Humira biosimilar (adalimumab) development sample,… Read More

#News

#Antibodies #Biosimilars #Kinetics #Screening

Fcγ Receptor and Antigen Kinetic Screening for Rapid Biosimilar Downstream Processing Assessment

Demonstrating similarity of biomolecules such as antibodies throughout upstream and downstream production processes is crucial. A rapid testing method is demonstrated using a Humira biosimilar (adalimumab) development sample, which assesses compatibility with three essential ligands in compliance with regulatory standards. This Application Note covers: How to rapidly assess column elution… Read More

#Resources

#Biosimilars #IQVIA #Market reporting #United States

US drugs market grows by 5% in 2022

The US market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis. This was driven by a range of factors, including an increase in health services utilisation, which is now back to pre-pandemic levels, and the entry of new medicines into… Read More

#Editor's Choice #Market Reports #News

European Commission
#Biosimilars #Comment #European Commission #Opinion #Pharma #Regulatory

European Commission vs Big Pharma, or profit vs access?  

On January 31 2023, an internally circulated version of the European Commission’s overhaul of the EU’s pharma legislation was leaked, and published by Politico1. Politico published a summary of the key propositions outlined in the draft2, and DDW’s Multimedia Editor Megan Thomas investigates their intention, and observes how the industry… Read More

#Exclusive Content #Opinion #Regulatory